https://etira.life/wp-content/uploads/2022/07/Scientific-Thumbnail.jpg661648Etirahttps://etira.life/wp-content/uploads/2023/11/etira-life-logo-home.pngEtira2022-07-01 09:23:172023-11-30 13:02:24Scientific News Media Features the Discovery of ERX-41, the Novel Mechanism of Action and Novel Molecular Target
Patients must be at least 18 years of age at the time of signing the informed consent.
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial, and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective
Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
Adequate baseline organ function and hematologic function
Life expectancy >3 months
Exclusion criteria
Systemic anti-cancer therapy within 4 weeks of first dose of study drug
Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.
Uncontrolled intercurrent illnesses
Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.
Scientific News Media Features the Discovery of ERX-41, the Novel Mechanism of Action and Novel Molecular Target
News